« Return to News | Awards & Advancement

Blueprint Medicines names Christoph Lengauer chief scientific officer

Friday, February 10, 2012 11:44 AM

Blueprint Medicines, a Cambridge, Mass.-based developer of personalized cancer therapies, has appointed Christoph Lengauer, Ph.D., chief scientific officer.

Lengauer most recently was vice president and global head of oncology drug discovery and preclinical development at Sanofi. Previously, he was executive director and senior unit head, oncology discovery at the Novartis Institutes for Biomedical Research, and an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.

Lengauer has a proven track record in cancer drug discovery, including contributing to 17 development candidates, 11 drugs/programs that reached first-in-human clinical trials and two registered drugs. He is lead or senior author of several scientific articles published in journals such as Cell, Nature and Science.

"Christoph has been at the forefront of the development of several novel and effective cancer drugs that have had a significant impact on patients' lives and brings a powerful understanding of cancer drug development to Blueprint," said Nicholas Lydon, Ph.D., scientific co-founder of Blueprint Medicines. "He is uniquely suited to lead our cancer therapeutics development strategy, and we believe his appointment is a true validation of the potential of Blueprint Medicines' platform and our ability to leverage emerging molecular insights to develop genomically-driven, highly selective therapies."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.